S5 Table. Characteristics of patients with stable disease or pseudoprogression

	Stable disease (n=260)	Pseudo progression (n=17)	p-value
Age (yr)	72.0±8.6	68.3±8.5	0.082
BMI (kg/m^2)	23.8±3.3	24.9±2.5	0.250
PSA (pre-treatment) (ng/dL)	39.0 (10.3-146.6)	28.5 (7.7-84.4)	0.866
ECOG score 0-1	237 (91.2)	16 (94.1)	0.674
HTN	110 (42.1)	5 (29.4)	0.317
DM	54 (20.7)	4 (23.5)	0.736
Cardiovascular disease	24 (9.2)	2 (11.8)	0.701
Primary treatment			
Radical prostatectomy	49 (18.8)	5 (29.4)	0.283
Radiotherapy	84 (32.2)	8 (47.1)	0.207
Timing of enzalutamide			0.723
Pre-docetaxel	142 (54.4)	10 (58.8)	
Post-docetaxel	119 (45.6)	7 (41.2)	
Metastasis type			
Bone metastasis only	175 (77.4)	15 (93.8)	0.125
Visceral metastasis only	4 (1.6)	1 (5.9)	0.200
Both bone and visceral metastasis	29 (11.4)	1 (5.9)	0.484
No. of bone metastasis			0.08
< 10	126 (68.5)	6 (46.2)	
10-20	36 (19.6)	6 (46.2)	
> 20	22 (12.0)	1 (7.7)	
ISUP GG			0.082
1-3	62 (25.5)	1 (6.3)	
4-5	181 (74.5)	15 (93.7)	
Cycle of enzalutamide	14.8±12.5	19.2±15.6	0.170

Values are presented as mean±SD, median (IQR), or number (%). BMI, body mass index; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; ISUP GG, International Society of Urological Pathology Grade Group; PSA, prostate-specific antigen; SD, standard deviation.